Francis Farhadi
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Francis Farhadi sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Francis Farhadi: 8 sponsored US clinical trials, 6 recruiting.
Francis Farhadi sponsors 8 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cervical Myelopathy, with 2 trials.
Upper-quartile sponsor footprint
Francis Farhadi sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Evaluating Safety and Feasibility of Transcutaneous Spinal Cord Stimulation Following Traumatic and Non-Traumatic Spinal Cord Injury: A Pilot Study
NCT06520020
Spinal Decompression Plus Nerve Graft Implantation Following TSCI
NCT06243211
Degenerative Cervical Myelopathy Repository
NCT05446259
Prospective Analysis of Spinal Epidural Abscess
NCT05464251
Spinal Cord Injury Neuroprotection With Glyburide
NCT05426681
Thoracic-Lumbar Arthrodesis- Implanet Jazz
NCT05366140
Lumbar Fusion With Porous Versus Non-Porous Cages
NCT05583864
MMG vs. EMG for Cortical Breach Detection
NCT05352048
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
What is open in the Francis Farhadi pipeline
6 recruiting of 8 indexed (75% open); 1 completed (13%).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Cervical Myelopathy (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Francis Farhadi: open-pipeline peers nationwide
Peers matched on 8 registered trials and 75% open enrollment, not the therapeutic-area sidebar.
Francis Farhadi sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 75% open enrollment (± trial volume)
- A2 Biotherapeutics · 75% recruiting · 4 trials
- Acepodia Biotech · 75% recruiting · 4 trials
- American Laboratory Products Company · 75% recruiting · 4 trials
- Amryt Pharma · 75% recruiting · 4 trials
Related
What to do with this Francis Farhadi page
8 registered trials is a research-attention snapshot, not an endorsement of Francis Farhadi or any single study.
- 6 of Francis Farhadi's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cervical Myelopathy is the condition Francis Farhadi studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cervical Myelopathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Francis Farhadi pipeline card: 8 registered trials from official public datasets.Report a data error.